Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

French (CAC) Healthcare Sector Analysis

UpdatedApr 14, 2026
DataAggregated Company Financials
Companies54
  • 7D-0.5%
  • 3M-14.2%
  • 1Y-8.0%
  • YTD-12.5%

The Healthcare is pretty flat in the last 7 days, but EssilorLuxottica Société anonyme has stood out, gaining 3.0%. As for the longer term, the industry has declined 8.0% in the last year. As for the next few years, earnings are expected to grow by 18% per annum.

Sector Valuation and Performance

Has the French Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 14 Apr 2026€261.6b€117.2b€7.5b19.9x34.9x2.2x
Thu, 12 Mar 2026€262.2b€117.1b€7.6b20.7x34.3x2.2x
Sat, 07 Feb 2026€289.2b€115.7b€7.7b22.1x37.5x2.5x
Mon, 05 Jan 2026€299.4b€114.8b€9.2b20.7x32.4x2.6x
Wed, 03 Dec 2025€313.7b€114.8b€9.5b20.7x33x2.7x
Fri, 31 Oct 2025€322.0b€114.8b€9.5b22.3x33.8x2.8x
Sun, 28 Sep 2025€284.2b€114.6b€9.3b21.4x30.6x2.5x
Tue, 26 Aug 2025€296.9b€114.3b€9.3b20.8x31.8x2.6x
Thu, 24 Jul 2025€281.9b€112.6b€9.0b22.9x31.2x2.5x
Sat, 21 Jun 2025€278.3b€112.6b€9.0b24.1x31x2.5x
Mon, 19 May 2025€296.2b€112.6b€8.8b23.9x33.7x2.6x
Wed, 16 Apr 2025€287.8b€111.3b€10.1b20.4x28.5x2.6x
Fri, 14 Mar 2025€316.6b€111.2b€10.1b24x31.3x2.8x
Sun, 09 Feb 2025€317.5b€110.0b€10.3b20.4x30.9x2.9x
Tue, 07 Jan 2025€286.8b€113.9b€9.1b21.4x31.6x2.5x
Thu, 05 Dec 2024€277.8b€113.9b€9.1b21x30.7x2.4x
Sat, 02 Nov 2024€284.4b€113.9b€9.1b22.3x31.3x2.5x
Mon, 30 Sep 2024€291.9b€112.3b€8.7b23.3x33.6x2.6x
Wed, 28 Aug 2024€286.5b€111.8b€8.6b22.9x33.3x2.6x
Fri, 26 Jul 2024€270.0b€110.3b€9.0b23.2x29.9x2.4x
Sun, 23 Jun 2024€263.6b€110.0b€9.0b22.7x29.2x2.4x
Tue, 21 May 2024€273.1b€110.0b€9.0b24.2x30.3x2.5x
Thu, 18 Apr 2024€266.9b€104.7b€8.6b20.4x31.1x2.5x
Sat, 16 Mar 2024€274.4b€104.7b€8.5b20.8x32.2x2.6x
Mon, 12 Feb 2024€260.7b€104.7b€9.2b20.3x28.2x2.5x
Wed, 10 Jan 2024€270.0b€104.0b€12.7b21.5x21.3x2.6x
Fri, 08 Dec 2023€250.4b€104.0b€12.7b20.6x19.7x2.4x
Sun, 05 Nov 2023€246.2b€104.3b€12.8b20.8x19.2x2.4x
Tue, 03 Oct 2023€268.9b€104.9b€12.5b22.2x21.5x2.6x
Thu, 31 Aug 2023€275.2b€104.8b€12.4b22.6x22.1x2.6x
Sat, 29 Jul 2023€275.7b€104.6b€12.2b21.8x22.6x2.6x
Mon, 26 Jun 2023€265.0b€103.8b€12.4b19.4x21.4x2.6x
Wed, 24 May 2023€276.2b€108.3b€12.1b20.9x22.9x2.5x
Fri, 21 Apr 2023€275.2b€107.7b€12.2b20.7x22.6x2.6x
Price to Earnings Ratio

22.6x


Total Market Cap: €275.2bTotal Earnings: €12.2bTotal Revenue: €107.7bTotal Market Cap vs Earnings and Revenue0%0%0%
French Healthcare Sector Price to Earnings3Y Average 29.2x202420252026
Current Industry PE
  • Investors are optimistic on the French Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 34.9x which is higher than its 3-year average PE of 29.2x.
  • The 3-year average PS ratio of 2.6x is higher than the industry's current PS ratio of 2.2x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 15% per year over the last three years.
  • Meanwhile revenues for these companies have grown 2.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the French Healthcare sector?

FR Market2.97%
Healthcare-0.47%
Healthtech4.28%
Biotech2.58%
Medical Equipment2.24%
Life Sciences0.41%
Healthcare Services-0.69%
Pharma-3.27%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 46.0x.
    • Analysts are expecting annual earnings growth of 19.4%, which is higher than its past year's earnings growth of 16.8% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 61% over the next 5 years.
  • This is better than its past earnings growth rate of 8.9% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 14% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
EL EssilorLuxottica Société anonyme€197.053.0%
+€2.7b		-20.3%PE39.3x
DIM Sartorius Stedim Biotech€173.902.8%
+€467.0m		2.3%PE63.7x
ABVX ABIVAX Société Anonyme€104.803.4%
+€269.2m		1,855.2%PS1815.9x
VIRP Virbac€359.502.4%
+€71.2m		21.3%PE20x
ALCLS Cellectis€3.7019.2%
+€43.2m		160.9%PS4x

Latest News

EMEIS
€13.47
emeis Société anonyme
7D
-1.7%
1Y
25.6%
ALERS
€24.00
Eurobio Scientific Société anonyme
7D
6.7%
1Y
-2.9%
SAN
€79.41
Sanofi
7D
-3.8%
1Y
-13.6%
ABVX
€104.80
ABIVAX Société Anonyme
7D
3.4%
1Y
1,855.2%
IPN
€166.40
Ipsen
7D
-0.7%
1Y
70.8%

IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook

Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view. Analyst Commentary Bullish Takeaways Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.
BIM
€90.00
bioMérieux
7D
-3.9%
1Y
-21.7%

BIM: Food Diagnostics Expansion And Dividend Support Will Drive Future Returns

Analyst price targets for bioMérieux have been revised lower to €100. This reflects a slightly reduced fair value estimate and Street research pointing to more cautious views on the shares, while still assuming broadly unchanged revenue growth, profit margin and P/E expectations.
BOI
€26.50
Boiron
7D
-5.4%
1Y
11.8%
DIM
€173.90
Sartorius Stedim Biotech
7D
2.8%
1Y
2.3%
IVA
€4.41
Inventiva
7D
-6.6%
1Y
55.6%

IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Narrative

The analyst price target for Inventiva has shifted from €8.98 to about €10.00, reflecting updated analyst views that balance a slightly higher discount rate with Street research highlighting lanifibranor's profile in MASH and recent supportive coverage from multiple firms. Analyst Commentary Street research around Inventiva centers on how effectively the company can turn lanifibranor's MASH profile into a de-risked late stage asset and how that potential squares with recent price target resets and rating changes.
ERF
€64.90
Eurofins Scientific
7D
-3.0%
1Y
30.5%

ERF: Revised Assumptions And Expanded Capabilities Will Support Future Re Rating Potential

Analysts have increased their price target on Eurofins Scientific by €10.20, citing updated assumptions about discount rates, revenue growth, profit margins and future P/E as the key drivers of the change. Analyst Commentary Bullish analysts are reacting positively to the revised price target on Eurofins Scientific, pointing to updated assumptions around discount rates, revenue growth, profit margins and future P/E as key inputs behind the higher valuation range.
NANO
€26.36
Nanobiotix
7D
-3.8%
1Y
778.7%
EL
€197.05
EssilorLuxottica Société anonyme
7D
3.0%
1Y
-20.3%
EQS
€40.10
Equasens Société anonyme
7D
5.5%
1Y
7.2%
VETO
€79.50
Vetoquinol
7D
1.4%
1Y
4.2%
ALCLS
€3.70
Cellectis
7D
19.2%
1Y
160.9%
VIRP
€359.50
Virbac
7D
2.4%
1Y
21.3%